Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Vertiseit subsidiary Grassfish extends global Porsche agreement until 2031

Vertiseit subsidiary Grassfish extends global Porsche agreement until 2031

BitgetBitget2026/11/04 10:34
  • Vertiseit subsidiary Grassfish extended its global framework agreement with Porsche through 2031.
  • The agreement covers an In-Store Experience Management platform and solution development for approximately 900 Porsche dealerships worldwide.
  • No volume commitments are included, but the agreement enables further expansion across Porsche's global dealership network.
  • Porsche has partnered with Grassfish since 2020, with more than 10,000 touchpoints currently running on its platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertiseit AB (publ) published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12